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ABSTRACT To investigate the role ofan anchoring pocket
in aflele-specific peptide presentation by a major histocompat-
ibility complex class I molecule, we "transplanted" a B pocket
from HLA-A*0201 into HLA-B*2705 by site-directed muta-
genesis. The resulting protein, designated B27.A2B, binds a
different set of endogenous peptides than B*2705 as evidenced
by complete loss of allorecognition as well as restored expres-
sion in the antigen processing-defective mutant cell line T2.
B27.A2B also fails to present an HLA-B27-restricted influenza
virus peptide [nucleoprotein (383-391)] to cytotoxic T lympho-
cytes (CTLs). However, substitution of leucine, the predomi-
nant P2 anchor residue in A*0201-restricted peptides, for
arginine, the P2 anchor in nucleoprotein-(383-391) and other
B*2705-restricted peptides, restores recognition ofB27.A2B by
the same B*2705-restricted peptide-specific CTLs. These re-
sults demonstrate that a dominant polymorphic pocket in a
class I molecule, through interaction with the anchor residue of
an antigenic peptide, can distinguish among peptides differing
by only a single amino acid and thus determine the allelic
specifi'city of peptide presentation.
Class I major histocompatibility complex molecules bind and
present peptide antigens to T-cell receptors (TCRs) on cyto-
toxic T lymphocytes (CTLs). For the immune system to
discriminate between self and nonself, and respond to a wide
variety of invading pathogens, class I proteins must bind
peptides of diverse amino acid sequences and yet maintain
allelic specificity. With the combination of structural and
functional studies, many of the principles that govern this
process are beginning to emerge.
The class I antigen binding groove consists of six pockets
(A-F) that vary in shape, depth, and chemical composition
and appear to accommodate different structural features of
bound peptides (1-10). Pockets A and F, located at either end
of the groove, are composed mainly of conserved residues
that form hydrogen bonds with the N and C termini of
peptide, respectively (6-10). These hydrogen bonds in addi-
tion to interactions between other conserved class I residues
and the peptide backbone, as opposed to interactions with
peptide side chains, are the main determinants of peptide
binding affinity (6-10).
In contrast to pockets A and F, pockets B-E contain many
polymorphic residues and appear to influence what peptides
will bind to a class I molecule. For example, HLA-B*2705,
which contains a deep B pocket with a negatively charged
glutamic acid at position 45, and other polar residues at
positions 9 (histidine) and 24 (threonine), binds peptides with
arginine at position 2 (ArgP2) (11), while HLA-A*0201 has
hydrophobic residues in these positions (Met45, Phe9, Ala24)
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and binds peptides with predominantly LeuP2 (with some
Met"2 and IleP2) (12). It has been hypothesized that these
allele-specific peptide residues or anchors interact specifi-
cally with dominant pockets in the class I molecule and that
shallow pockets would have less-stringent requirements and
accommodate many different side chains (13). It should be
noted that the B pocket is not always dominant and in some
alleles may be quite small (e.g., H-2Kb) (6, 8) or even
obstructed by large bulky residues (e.g., HLA-B*0801) (14)
so that it will not accommodate a peptide side chain. In these
instances, other pockets appear to be dominant and contain
anchor residues (6, 8).
The B pocket has also been implicated as an important
structural component in the association between HLA-B27
and susceptibility to spondyloarthropathies, since it is con-
served in all disease-associated B27 subtypes (reviewed in
ref. 15). While the mechanism(s) responsible for this associ-
ation remains unclear, it has been hypothesized that "arthri-
togenic" peptides displaying the ArgP2 motif like other B27-
associated peptides may be important in disease pathogenesis
(16). A better understanding of the role the B pocket plays in
peptide selection may help to define disease-associated pep-
tides and aid in designing strategies to block their interaction
with B27. To investigate the role of the B pocket in deter-
mining allele-specific peptide presentation, we have trans-
planted a B pocket from HLA-A*0201 into HLA-B*2705.
MATERIALS AND METHODS
HLA-B*2705 Mutant Genes, Cell Transfections, and Flow
Cytometry. Four to six amino acids in the B pocket of
HLA-B*2705 were changed to the corresponding HLA-
A*0201 residues by site-directed mutagenesis (Altered Sites;
Promega) and confirmed by DNA sequencing. A list of these
mutants and the amino acids that compose their B pockets
compared with HLA-B*2705 and -A*0201 is shown in Table
1. Mutant B*2705 genes and pSV2neo were linearized with
HindIII and BamHI, respectively, and cotransfected into the
HLA-A negative and -B35 low (17) cell line HMy2.ClR (C1R)
(18) or the antigen processing-defective line 0.174 x CEMR
(T2) (19) by electroporation (Gene Pulser; Bio-Rad). Positive
transfectants were selected with Geneticin (G418) at 1.8
mg/ml (1.2 mg/ml for T2 cells) and then maintained at 0.4
mg/ml. Cell-surface expression ofthe products oftransfected
or endogenous class I genes was determined by indirect
immunofluorescence with ME.1 (anti-HLA-B27, -B7, -B42)
(20) or MA2.1 (anti-HLA-A2) (21) and fluorescein isothio-
cyanate (FITC)-conjugated goat anti-mouse IgG followed by
analytical flow cytometry (Epics 7-52). Cells expressing
mutant B27 molecules at levels equivalent to B*2705 (in C1R)
Abbreviations: CTL, cytotoxic T lymphocyte; TCR, T-cell receptor;
NP, nucleoprotein; FITC, fluorescein isothiocyanate.
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Table 1. HLA-B*2705 B pocket mutants
Amino acid residue
Name 9 24 45 66 67 70
B*2705 H T E I C K
B27.A24 H A E K V H
B27.A25 H A M K V H
B27.A2B F A M K V H
A*0201 F A M K V H
Bottom and inner walls of the B pocket are formed by His9, Thr24,
VaI34, Glu45, and Cys67, while Tyr7, Glu63, Lys70, and Tyr99 surround
the rim (4). Using site-directed mutagenesis, changes were made at
several codons in the B*2705 gene to encode HLA-A*0201 residues
at four, five, or six of the B pocket positions that differ between these
two molecules. The B27.A2B gene encodes a B*2705 molecule
whose B pocket is identical to that of HLA-A*0201.
were isolated by fluorescence-activated cell sorting and used
for these studies.
The raw data for the histograms shown in Fig. 2 are
obtained as cell number (y axis) in each of 256 channels that
span 3 orders of magnitude of fluorescence intensity (arbi-
trary units; x axis). To reflect the logarithmic nature of this
scale, where small peak shifts represent large changes in
surface expression, these channels are expressed as 3 log
units (85 channels per unit).
Peptides. The following peptides were used: nucleoprotein
(NP)-(383-391), SRYWAIRTR derived from the influenza A
X/31 NP; NP-(383-391;L384), SLYWAIRTR; NP-(383-
391;K384), SKYWAIRTR; NP-(383-391;K389), SRY-
WAIKTR; NP-(383-391;K391), SRYWAIRTK. Peptides
were synthesized on a Biosearch 9500 automated synthesizer
by tert-butoxycarbonyl chemistry, or with a multipeptide
synthesis block using 9-fluorenylmethoxycarbonyl chemis-
try, and HPLC purified prior to use.
CTL Lines and Clones. Alloreactive CTL lines specific for
HLA-B27 were grown from peripheral blood mononuclear
cells obtained from a healthy donor (DQ; HLA-A1, -A33,
-B8, -Bw6, -Cw6) and stimulated weekly with mitomycin
C-treated ClR expressing B*2705. Autologous HLA-B*2705-
restricted CTL lines HF (HLA-A2, -A3, -B7, -B*2705) and
SD (HLA-A2, -A32, -B*2705, -B49, Bw4) were grown from
peripheral blood mononuclear cells that had been preincu-
bated for 1 h with influenza A X/31 virus in the absence of
serum and then for 7 d in RPMI 1640 medium with 10% fetal
calfserum (22, 23). Cells from these bulk cultures were mixed
with autologous B-lymphoblastoid cells preincubated for 1 h
with influenza A NP-(383-391) at 50 ug/ml and irradiated
with 3000 rad (1 rad = 0.01 Gy) and grown in medium
containing recombinant interleukin 2 (10 units/ml) (Cetus).
CTL lines were maintained in culture by restimulation every
10-14 d with autologous irradiated B-cell lines, which had
been pulsed with peptide for 1 h. These lines were shown to
be specific for the stimulating peptide presented by HLA-B27
(unpublished data). CTL clones specific for the NP-(383-391)
peptide on HLA-B*2705 were obtained by limiting dilution
(0.3 cell per well) of SD CTLs.
Cytotoxicity Assay. Alloreactive and influenza-specific
CTL lines and clones were tested for recognition of mutant
B*2705 molecules in a standard 4-h 51Cr-release cytotoxicity
assay (24). Specific lysis was quantitated as follows:
% specific lysis =
[(cpmample- CPmspont)/(CPmma -cPmspont)] X 100.
Spontaneous release (cpmspont) is determined from targets
incubated with medium alone and maximal release (cpmmax)
is determined from targets incubated with 5% Triton X-100.
Spontaneous and maximal release for each condition are
performed in quadruplicate, while experimental points rep-
resent triplicate or duplicate determinations. Positive con-
trols for all CTL assays are represented by ClR transfected
with wild-type B*2705 (and pSV2neo), and negative controls
are ClR transfected with pSV2neo alone. All CTL assays
have been performed at least twice with the same results.
RESULTS
Alloreactive CTL Recognition of B*2705 B Pocket Mutants.
Using the HLA-B*2705 gene as a starting point, we con-
structed three mutants encoding B*2705 with four (B27.A24),
five (B27.A25), or six (B27.A2B) substitutions to HLA-
A*0201 residues in the B pocket. In B27.A2B, the B pocket
is identical to HLA-A*0201, while the two other molecules
contain B27 residues at positions 9 (histidine) and 9 (histidine)
and 45 (glutamic acid) (Table 1). When transfected into ClR
cells, these mutants are expressed on the cell surface at levels
comparable to B*2705 asjudged by cell-surface staining with
the monoclonal antibody ME.1 and flow cytometry (unpub-
lished data). However, these mutants are not recognized by
B*2705-specific alloreactive CTLs (Fig. 1). A second allore-
active CTL line from a different individual yields the same
results (unpublished data). Since B pocket residues are not
accessible to the TCR (4,7) and thus should not directly affect
CTL recognition, it appears likely that the self peptides
presented by these mutants are different.
Expression of B27.A2B in T2 Cells. Further evidence for
altered peptide binding specificity of the B27 molecule con-
taining an A2-like B pocket was demonstrated by transfecting
B27.A2B into the antigen processing-defective cell line T2.
These cells synthesize class I heavy chains (HLA-B5 and
-A2) and 182-microglobulin but, because of a large deletion in
the class II region of chromosome 6, do not transport
cytoplasmic peptides into the endoplasmic reticulum and
therefore do not express stable HLA-B5 on the surface (19,
25-27). HLA-A2 is expressed, but only at 20-30% of control
levels (19), which appears to be due to the binding ofpeptides
derived from signal sequences (28, 29). T2 cells transfected
with HLA-B*2705 express this molecule at only 10-20% of
control levels (compared with B*2705 in C1R) but display a
3- to 4-fold increase in surface expression when incubated
with the B27-restricted peptide NP-(383-391) (Fig. 2C). T2
cells transfected with B27.A2B express this molecule at
levels 3- to 4-fold greater than B*2705 in T2 (Fig. 2F) and at
70-80%o the level of B*2705 in ClR (data not shown). While

















FIG. 1. Lack of recognition of B*2705 B pocket mutants by
alloreactive CTLs. ADQ CTL line that recognizes B*2705 was tested
for its ability to recognize and lyse ClR cells transfected with the B
pocket mutant B27.A24 (O), B27.A25 (+), or B27.A2B (o) in a
standard 4-h 51Cr-release assay. Positive and negative controls are
represented by ClR-B*2705 (e) and C1R-Neo (A), respectively. E:T,
effector (CTL)/target cell ratio.
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FIG. 2. Increased cell-surface expression ofB*2705 in T2 B*2705
cells after incubation with NP-(383-391) peptide or after B pocket
transplant. (A-C) Expression of HLA-A*0201 (B; MA2.1) and
-B*2705 (C; ME.1) in T2 B*2705 cells incubated with (thick lines; +
peptide) or without (- peptide) NP-(383-391) peptide (100 ,uM for 12
h) is shown. (D-F) Cell-surface expression of HLA-A*0201 (E;
MA2.1) and -B*2705 or B27.A2B (F; ME.1) in T2-B*2705 and T2
B27.A2B (thick lines) cells. FITC staining alone (without first
antibody) is shown inA and D. Histograms show cell number in each
of 256 channels spanning 3 logs of fluorescence intensity and are
overlaid for ease of comparison.
more heavy chain than T2 B*2705, this would be unlikely to
account for the increased surface expression of B27.A2B,
since peptide supply is still the limiting factor (see Fig. 2C;
see also refs. 26 and 27). Thus, expression of B27.A2B in T2
is comparable to HLA-A*0201 or -B*2705 stabilized with
exogenous peptide, suggesting that this B27 molecule with an
A2-like B pocket may be binding signal sequence-derived
peptides similar to those bound to A*0201 or perhaps other
as yet unidentified sequences. The small decrease in expres-
sion of A*0201 seen in T2 cells transfected with B27.A2B
(Fig. 2E) is consistent with the idea that B27.A2B is com-
peting for a limiting number of signal sequence peptides that
would otherwise bind to A*0201. It is worth noting that T2
transfected with B27.A24 showed no surface expression of
this molecule (unpublished data), suggesting that an A2-like
B pocket with B27 residues at positions 9 (histidine) and 45
(glutamic acid) confers different peptide binding specificity
than either an A2 or B27-like B pocket. Our attempts at
transfecting B27.A25 into T2 have so far been unsuccessful.
Recognition of B*2705 B Pocket Mutants by NP-(383-391)
Peptide-Specific CTLs. To examine the presentation ofa single
peptide by these B pocket mutants, we chose an HLA-B27-
restricted influenza A NP epitope, NP-(383-391) (22, 23, 30).
All three mutants fail to present this peptide to a B27-restricted
peptide-specific CTL line (HF). The same result is seen with
virus infection or incubation of target cells with the optimal
nonamer peptide NP-(383-391) (SRYWAIRTR) (Fig. 3),
which contains an ArgP2 residue similar to other B27-restricted
peptides (11, 22). If the B pocket is binding the side chain of
P2, then transforming the B pocket of B27 into an A2-like
structure should change the specificity of this interaction and
favor binding of a peptide with LeuP2 and not ArgP2. To test
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FIG. 3. Lack ofrecognition by influenzaA NP-(383-391)-specific
CTLs of B pocket mutants incubated with NP-(383-391) peptide or
infected with influenza A X/31 virus. (A) Target cells were incubated
with effectors for 4 h at an effector/target cell ratio of 5:1 at the
indicated peptide concentrations. e, B*2705; o, Neo; o, B27.A2B;
O, B27.A24; +, B27.A25. (B) Target cells were labeled with Na51Cr
for 1 h, washed, divided into three aliquots, and then further
incubated for 1 h with influenza A X/31 virus at a final hemagglu-
tinating titer of 1:500 in the absence of serum (flu), medium alone (-
peptide), or NP-(383-391) at a final concentration of 10 ,uM (+
peptide). At the end of 1 h, all targets were diluted 1:75 and flu-infected
targets were then incubated for another 3 h. A CTL assay was then
performed, with targets and effectors plated at the indicated effector/
target cell (E:T) ratios, and percentage specific lysis was detennined
after the standard 4-h incubation. o, B2705 - peptide; *, B2705 +
peptide; O, B2705 + flu; A, B27.A2B - peptide; A, B27.A2B +
peptide; +, B27.A2B + flu; v, B27.A25 - peptide; v, B27.A25 +
peptide; +, B27.A25 + flu; o, B27.A24 - peptide; *, B27.A24 +
peptide;*, B27.A24 + flu.
391) peptide SLYWAIRTR. The B27.A2B mutant presents
this peptide to the same HFCTLs that recognize NP-(383-391)
on B*2705, while presentation by B*2705 and B27.A25 is
100-fold less (Fig. 4). B27.A24 is not lysed any better than the
ClR-Neo negative control. The small increase in lysis ob-
served for B*2705 and B27.A25, compared to Neo and
B27.A24, is unlikely to be physiologically relevant since the
peptide concentrations required for this effect are in the
10-100 ,uM range (i.e., 100- to 1000-fold greater than for the
B27.A2B molecule). A similar result showing pocket speci-
ficity for the P2 side chain is obtained with a CTL clone
derived from a different individual (SD) (Fig. 5).
Specificity of the B Pocket for Arginine. To investigate the
specificity of the B*2705 B pocket for arginine (7), lysine,
which is also positively charged and approximately the same
length as arginine, was substituted for arginine at P2 in the
NP-(383-391) peptide (SKYWAIRTR). This conservative
substitution nearly completely abolishes peptide presenta-
tion, while an arginine to lysine substitution at P9, an area
that binds in the F pocket (31), has no deleterious effect (Fig.
6). An arginine to lysine substitution at P7, another peptide
a)-0E
0
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FIG. 4. Restored recognition by influenza A NP-(383-391)-
specific CTLs of the B27.A2B mutant by substituting a leucine at
P2 in the NP-(383-391) peptide. Experiment was performed exactly
as described in Fig. 3A, except LeuP2-substituted NP-(383-391)
(SLYWAIRTR) was used. *, B*2705; o, Neo; o, B27.A2B; O,
B27.A24; +, B27.A25.
side chain that interacts with the B27 molecule (5), also
significantly reduces presentation. In addition, none of the
mutant molecules (B27.A2B, B27.A25, or B27.A24) is rec-
ognized with the LysP2 peptide (unpublished data), consistent
with the observed specificity of an A2-like B pocket for
hydrophobic side chains (leucine, methionine, or isoleucine)
(12).
DISCUSSION
Previous studies have shown that single B pocket mutations



































FIG. 5. Recognition of the NP-(383-391) (ArgP2)-B*2705 com-
plex by the same clone that recognizes the NP-(383-391) LeuP2-
B27.A2B complex. CTL assay was done at various concentrations of
SBYWAIRTR (A) or SLYWAIRTR (B). Clone was obtained by
limiting dilution ofbulk SD CTLs, and assay was performed using an
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FIG. 6. Specificity ofthe B pocket in HLA-B27 for arginine at P2
of the influenza A NP-(383-391) peptide. CTL assay was performed
in the presence of NP-(383-391) (SRYWAIRTR) (o) or with the
following lysine-substituted peptides: K384, SKYWAIRTR (m);
K389, SRYWAIKTR (e); K391, SRYWAIRTK (o) at an effector/
target cell ratio of 5:1.
32-34). Single substitutions at positions 9, 24, 45, and 67 can
affect both selfpeptide and viral peptide presentation, but the
effect depends on the peptide being presented (34), its mode
of presentation (intra- vs. extracellular) (M. Matsui and
J.A.F., unpublished work), and/or the particular CTL line or
clone used. It is clear from these functional studies that
individual residues in the B pocket can influence binding of
some (but probably not all) self peptides and viral epitopes
and therefore affect recognition by their cognate peptide-
specific CTLs. We have addressed the function of the B
pocket as an entire unit and show that by "transplanting" a
B pocket from HLA-A*0201 into HLA-B*2705 we have
changed the specificity of the class I molecule for peptides in
an allele-specific fashion. Peptides with Arge2 are no longer
recognized on B*2705 with an A2-like B pocket, while the
single substitution of leucine for arginine at P2 restores
recognition. These results are consistent with the ArgP2 (but
not LeuP2) side chain binding in a B27-like B pocket and,
conversely, the LeuP2 (but not ArgP2) side chain binding in an
A2-like B pocket. However, it should be noted that mutation
of class I residues could abrogate CTL recognition indepen-
dent of peptide binding. This is unlikely to be occurring here
for two reasons; first, the mutated residues are in the 13
pocket and are not directly accessible to the TCR (4, 7);
second, restored recognition with the LeuP2 peptide indicates
that essential TCR class I contact residues remain intact. In
addition, using the T2 assembly assay (35), we find that the
LeuP2 NP-(383-391) peptide will not promote assembly of
B27 molecules, even at concentrations up to 100 ,M (un-
published data). This same result for B*2705 has recently
been reported (36). As yet we have not been able to demon-
strate assembly of B27.A2B with the LeuP2 peptide. This
appears to result from an unusual stability of B27.A2B
compared with HLA-A2, -B5, and -B27 in T2 cells (unpub-
lished data), presumably because of the binding of peptides
present in the endoplasmic reticulum (28, 29).
We have demonstrated a striking specificity of the B27 B
pocket for arginine by showing that the conservative substi-
tution of lysine at P2 of the NP-(383-391) peptide abolishes
CTL recognition. This specificity, as suggested by Madden et
al. (7), may result from the planar configuration of hydrogen
bonds between the P2 guanidinium group and the side chains
ofHis9, Thr24, and Glu45. Thus lysine, which has a tetrahedral
amino group at P2, may not be able to form stable hydrogen
bonds. The lack of presentation of the ArgP2 peptide by the
mutants with B27 residues at His9 (B27.A25) and His9 and
Glu45 (B27.A24) (Fig. 3A) demonstrates that while hydrogen
bonding between these residues and ArgP2 may be an impor-
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tant contributor to the free energy of peptide binding, it is
unlikely to be the only factor. Our studies also show that in
an A2-like B pocket, a single change from phenylalanine to
histidine at position 9 (B27.A25) is sufficient to greatly reduce
recognition with the LeuP2 peptide. This finding is consistent
with the results of Matsui et al. (ref. 32; M. Matsui and
J.A.F., unpublished work), where other mutations at position
9 (phenylalanine to leucine or phenylalanine to tyrosine) in
HLA-A*0201 affect recognition by many alloreactive A2-
specific clones, as well as recognition of FMP-(58-66) by
flu-specific CTLs. In addition, Rotzschke et al. (37) have
found that the HLA-A*0205 subtype of A2, which contains
tyrosine at position 9 (as well as three other non-B pocket
substitutions), loses the dominant leucine anchor residue at
P2 of eluted peptides, allowing polar residues such as gluta-
mine to bind. While it may be that other amino acids with
small side chains at P2, such as alanine or glycine, would be
tolerated in either a B27- or A2-like B pocket, their absence
from the pool of the most abundant self peptides (11, 12)
suggests that they do not compete effectively for binding with
endogenous peptides that contain arginine (for B27) or leu-
cine (for A2) at this position.
By transplanting a B pocket from one class I molecule into
another, we have demonstrated how class I molecules,
through the interaction between a dominant pocket and a
peptide anchor residue, can discriminate between nonamer
peptides differing by only a single amino acid. These results,
together with recent crystallographic analyses (6-10), pro-
vide direct evidence that while high-affinity peptide binding
may be a function primarily of conserved class I residues,
dominant pockets within the class I molecule can determine
the allelic specificity of peptides that are presented to the
TCR.
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